RESEARCH ARTICLE

Potential drug–drug interactions among elderly patients admitted to medical ward of Ayder Referral Hospital, Northern Ethiopia: a cross sectional study

Fantaye Teka¹, Gebrehiwot Teklay²*, Eskindeir Ayalew² and Terefe Teshome³

Abstract

Background: The elderly are considered as special population, as they differ from younger adults in terms of comorbidity, polypharmacy, pharmacokinetics, vulnerability to drug–drug interactions and adverse drug reactions. Despite the fact that the elderly patients are at high risk of having drug interaction and potential adverse outcomes, studies in this regard are scarce in resource limited settings like Ethiopia. The aim of this study was to assess the prevalence and determinants of potential drug–drug interaction in elderly patients admitted to medical ward of Ayder Referral Hospital in Northern Ethiopia.

Methods: A cross sectional study was conducted among elderly inpatients aged 60 years and above. The study was conducted from February to May 2014. Prescribed drugs being taken concurrently for at least 24 h were included and checked for drug–drug interaction using Micromedex® 2.0 online drug reference. Data were analyzed using statistical software, statistical package for social sciences for windows version 20. Logistic regression model was used to analyze factors associated with occurrence of drug interaction. P value of <0.05 was considered statistically significant.

Results: A total of 140 patients were participated in the study. The mean age (±standard deviation) of participants was 68 (±7) years. Majority (61.4 %) of patients were diagnosed with cardiovascular and/or renal diseases. A total of 814 drugs were prescribed with a mean of 6 (±4) medications per patient during a 13 (±9) days of hospital stay. About two-third (62.2 %) of the respondents were exposed to at least one potential drug–drug interaction. Among these 3.6, 32.9 and 25.7 % of patients had taken contraindicated drug combination, at least one major and at least one moderate drug–drug interaction, respectively. Patients with five or more prescribed medications were four times at risk of having drug–drug interaction (P = 0.00; adjusted odds ratio 4.047; 95 % confidence interval 1.867–8.775).

Conclusion: Drug–drug interaction in elderly patients was common in this resource limited set-up. Awareness creation and clinical pharmacist involvement in minimizing the risk associated with potentially harmful drug combinations are needed.

Keywords: Elderly, Drug–drug interaction, Polypharmacy, Ethiopia

Background

The ageing process is biological reality that has its own dynamic, largely beyond human control. The age of 65 and above, roughly equivalent to retirement ages in most developed countries is said to be the beginning of old age. However, this is not adapted well to the situation in developing countries like Africa. The United Nation (UN) agreed cutoff is 60 and above to refer to the older population [1] and this definition has gained acceptance in Ethiopian context as it coincides with the country’s official retirement age [2].

*Correspondence: tgebrehiwet@gmail.com
² Clinical Pharmacy Course and Research Unit, Department of Pharmacy, College of Health Sciences, Mekelle University, Mekelle, Ethiopia
Full list of author information is available at the end of the article

© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
The elderly differ from young adults in terms of comorbidity, polypharmacy, pharmacokinetics and greater vulnerability to adverse drug reactions (ADRs) [3]. Clinical trials are usually done in young adults excluding the elderly population. This brings a challenge in caring the elderly as findings obtained from trials may not be applicable to all real patients [4]. Along with age related gradual changes, the pharmacodynamics and pharmacokinetics of drugs in the elderly is altered. There are physiological changes that affect how medicines are handled, including alterations in drugs absorption, volumes of distribution, metabolism and clearance which can prolong half-life, increase potential for drug toxicity and the likelihood of ADRs [5–7]. In addition, there is alteration in drug response or sensitivity in the elderly probably due to changes in receptor numbers, changes in receptor affinity and age-related impairment of homeostatic mechanisms [4, 8].

Drug–drug interactions (DDIs) occurs when the effects of one drug is altered by another concomitantly administered drug [9]. The effect of a DDI might be apparent as decline in therapeutic effect of a drug, increased occurrence of ADRs and compromised treatment outcomes [10, 11]. Advanced age, polypharmacy and multiple prescribers have been identified as risk factors for occurrence of potential drug interactions [12]. DDIs are more likely to happen in the elderly because they tend to use multiple medications and have altered pharmacokinetics [6, 13]. A systematic literature review by Saedder et al. also identified number of drugs as the most frequently documented independent patient-related risk factor for serious ADRs in both the general adult population as well as in the elderly [14].

Drug interactions are considerable cause of ADRs and hospital admission. The incidence of DDI related ADRs in the elderly had been estimated to ranges from 4.5 to 6.5 % [15, 16]. In a systematic review and meta-analysis of observational study, DDI accounted for the 1.1 % hospital admissions and 0.1 % hospital visits [17]. More than half of all hospitalizations due to ADR had occurred in the elderly patients [18, 19]. Furthermore, DDI is associated with increased length of hospital stay and other added healthcare costs [20–22]. Despite the fact that the elderly patients are at high risk of having drug interaction and potential adverse outcomes, studies in this regard are scarce in resource limited settings like Ethiopia. The aim of this study was to assess the prevalence and determinants of potential DDIs in elderly patients admitted to medical ward of Ayder Referral Hospital (ARH) in Northern Ethiopia.

**Methods**

The study was conducted from February to May 2014 in ARH located in Mekelle city of Tigray Regional State, Northern Ethiopia. ARH is a teaching and the highest level medical facility in the northern part of the country. It provides general inpatient and outpatient services in four major departments (Internal Medicine, Pediatrics, Surgery, Gynecology and Obstetrics) and other specialty units [23]. A cross sectional study design was employed to assess drug–drug interactions in elderly patients. For this study, individuals aged 60 and above were included based on the UN’s definition of elderly [1] and this is the accepted cutoff for elderly population in Ethiopia [2]. Participants’ medical record was reviewed every 2 days from date of admission to date of discharge to see any added or discontinued treatments. Prescribed drugs being taken concurrently for at least 24 h were included and checked for drug–drug interaction using Micromedex® 2.0 online drug reference [24]. Micromedex® is medical software which gives evidence-based drug information about DDIs and potential ADRs. It categorizes drug combinations into contraindicated, major, moderate, and minor level of interaction based on the mortality and morbidity probabilities on patients.

**Definitions**

**Concurrent or concomitant drugs** Is defined as the concurrent use of drugs as prescribed by one or more different medical doctors not necessarily on the same day [25].

**Comorbidity** Is the presence of more than one distinct medical condition in an individual [26].

**Contraindicated DDI** The drug-pair is contraindicated for concurrent use [24].

**Major DDI** The interaction may have risk of death and/or require medical intervention to minimize or prevent some serious negative outcomes [24].

**Moderate DDI** It may have harmful effect on patient’s condition and can require change in the prescription [24].

**Polypharmacy** Is defined as the use of many drugs at the same time or the administration of an excessive number of drugs [27]. There is no standard cut point with regard to the number of medications that is agreed upon for the definition of polypharmacy. In this study, polypharmacy was operationalized to mean five drugs or more.

A sample of 140 elderly patients was studied. The sample size was determined using the formula for estimation of single proportion \( n = \left( Z \alpha / 2 \right)^2 p \left( 1 - p \right) / d^2 \) where \( Z = \) standard normal variable at 95 % confidence level (1.96), \( p = \) the prevalence of potential drug–drug interaction assumed to be 50 % and finally adjusted using correction formula for finite population. Study participants were selected by systematic random sampling techniques. List of admitted elderly patient at a particular time was considered as sampling frame. Sampling interval was obtained by dividing the number of elderly patients likely to be admitted during the study period...
divided by the sample size which gives 2 (300/140 = 2). The first patient was selected randomly and every other patient was included in the study.

Data were collected using a structured and pretested format that contains patient identification, medical profile and drugs prescribed. The data collectors were six final year pharmacy students, trained on how to approach study participants, ask for informed consent, abstract data from patient records and maintain the confidentiality of the collected data. Prior to the actual data collection, a pretest was done on six elderly patients (not included in this study) to check the practicability of the data collection format and procedures and to assess the performance of data collectors.

The evaluation of drug–drug interaction and data analysis was done by the investigators. Micromedex® 2.0 online drug reference [24] was used to check and describe the types of drug–drug interaction. Data were analyzed using statistical package for social sciences; for windows version 20 statistical software. The data were first checked for completeness then edited, cleaned and entered into the software. Descriptive statistics (frequencies, percentage, mean and standard deviation) were used to present counts, proportions and averages. Binary logistic regression model was used to analyze factors associated with occurrence of drug interaction. Output of the logistic regression was expressed as adjusted odds ratios at 95 % confidence intervals. P value of <0.05 was considered statistically significant.

Results

The medical records of 140 patients aged 60 years and above were utilized for the study. The mean age (±SD) of participants was 68 (±7) years. Almost half (52.1 %) of the study participants were male. The mean hospital stay of patients was 13 (±9) days. 38 % of the participants had comorbid conditions while 17.8 % of them had 5–8 and more than 8 prescribed drugs, respectively. Ceftriaxone was the most commonly used medication, prescribed in 55.75 % of the participants.

According to Micromedex® 2.0 online drug reference, nearly two-third (62.2 %) of the participants were exposed to at least one potential DDI. Among those 3.6, 32.9 and 25.7 % of elderly patients were prescribed a contraindicated drug combination, at least one major and at least one moderate DDI respectively. Clarithromycin with either simvastatin or ciprofloxacin was the only contraindicated drug combination in this study (Table 1).

The most frequently prescribed major DDIs were the combination of aspirin with either heparin or clopidogrel; warfarin with quinolone and macrolide antibiotics; and spironolactone with enalapril (Table 2).

There was no significant difference in the occurrence of DDI with respect to age, sex, presence of co-morbidities and length of hospital stay. DDI was found significantly associated with increase in number of drugs (polypharmacy) (P = 0.00; adjusted odds ratio 4.047; 95 % confidence interval 1.867–8.775) (Table 3).

Discussion

The mean (±SD) number of drugs prescribed per patient in this study was 6 (±4) which is almost similar to a study in Taiwan [28] 5.8 ± 2.4 but lower than study reports from Puducherry [29], India [30]; which was 7.61 ± 3.37 and 9.15 ± 0.03, respectively. These differences could be due to the difference in study set-up, health insurance policy, and difference in burden of co-morbidity and medication use pattern in these settings. In the current study, there is similar burden of infectious diseases (58.6 %) and cardiovascular diseases (61.4 %), where as in developed countries non-communicable diseases

| Drug combinations          | Number of patients | Documentation | Potential risks                                      |
|----------------------------|--------------------|---------------|-----------------------------------------------------|
| Clarithromycin simvastatin | 3                  | Good          | Increased risk of myopathy or rhabdomyolysis        |
| Clarithromycin ciprofloxacin | 1               | Fair          | Increased risk of QT interval prolongation           |
| Total                      | 4                  |               |                                                     |

* Documentation based on available studies or reports: good, studies strongly suggest that the interaction exists except proof of well-controlled studies; fair, available evidences are poor, but the interaction is suspected on the basis of pharmacologic considerations; or, evidences are good for an interaction of pharmacologically similar drug [24]
| Interacting drugs                  | Number of patients | Documentation | Potential risks                                                                 |
|----------------------------------|--------------------|---------------|---------------------------------------------------------------------------------|
| Anti TB(HRZ) + phenytoin         | 2                  | Good          | Decreased phenytoin and/or rifampin exposure                                     |
| Aspirin + cimetidine             | 1                  | ND            |                                                                                 |
| Aspirin + clopidogrel            | 5                  | Fair          | Increased risk of bleeding                                                      |
| Aspirin + enoxaparin             | 2                  | Good          | Increased risk of bleeding                                                      |
| Aspirin + fluoxetine             | 1                  | Good          | Increased risk of bleeding                                                      |
| Aspirin + omeprazole             | 1                  | ND            |                                                                                 |
| Ciprofloxacin + amitriptyline    | 1                  | Fair          | Increased risk of QT interval prolongation                                        |
| Ciprofloxacin + doxorubicin      | 1                  | Fair          | Increased doxorubicin exposure                                                  |
| Clarithromycin + amitriptyline   | 1                  | Fair          | Increased risk of QT-interval prolongation                                        |
| Clarithromycin + amiodipine      | 1                  | Excellent     | Increased amiodipine exposure                                                   |
| Clarithromycin + digoxin         | 2                  | Excellent     | Digoxin toxicity (nausea, vomiting, arrhythmias)                                |
| Clarithromycin + nifedipine      | 1                  | Moderate fair | Increased nifedipine plasma concentrations                                       |
| Clarithromycin + tramadol        | 3                  | Fair          | Increased risk for seizures, serotonin syndrome, and opioid-related toxicity     |
| Clarithromycin + atorvastatin    | 1                  | Good          | Increased risk of myopathy or rhabdomyolysis                                   |
| Clopidogrel + cimetidine         | 3                  | Fair          | Reduction in clinical efficacy of clopidogrel                                   |
| Clopidogrel + diclofenac         | 1                  | Excellent     | An increased risk of bleeding                                                   |
| Clopidogrel + omeprazole         | 1                  | Excellent     | Reduction in clinical efficacy of clopidogrel and increased risk for thrombosis |
| Cyclophosphamide + allopurinol   | 3                  | Good          | Cyclophosphamide toxicity (bone marrow suppression, nausea, vomiting)          |
| Cyclophosphamide + doxorubicin   | 3                  | Fair          | Increased risk of cardiomyopathy                                                |
| Heparin + aspirin                | 14                 | Fair          | Increased risk of bleeding                                                      |
| Heparin + enoxaparin             | 1                  | Fair          | Increased risk of bleeding                                                      |
| Heparin + clopidogrel            | 4                  | Fair          | Increased risk of bleeding                                                      |
| Heparin + diclofenac             | 1                  | Fair          | Increased risk of gastrointestinal bleeding                                      |
| Heparin + indomethacin           | 3                  | Excellent     | Increased risk of gastrointestinal bleeding; reduced effectiveness of indomethacin for the treatment of patent ductus arteriosus |
| Hydralazine + metformin          | 1                  | ND            | Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia    |
| Hydralazine + norfloxacin        | 1                  | ND            |                                                                                 |
| Insulin + norfloxacin            | 2                  | Fair          | Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia    |
| Insulin + ciprofloxacin          | 2                  | Fair          | Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia    |
| Potassium chloride + enalapril    | 2                  | Good          | Hyperkalemia                                                                    |
| Simvastatin + azithromycin       | 2                  | Good          | An increased risk of rhabdomyolysis                                             |
| Simvastatin + ciprofloxacin      | 2                  | Good          | Increased risk of myopathy or rhabdomyolysis                                   |
| Spironolactone + digoxin         | 2                  | Good          | Increased digoxin exposure                                                      |
| Spironolactone + enalapril       | 10                 | Good          | Hyperkalemia                                                                    |
| Spironolactone + potassium chloride | 4               | Fair          | Hyperkalemia                                                                    |
| Tramadol + chlorpromazine        | 2                  | Fair          | Increased risk of seizures                                                      |
| Tramadol + amitriptyline         | 1                  | Fair          | Increased risk of seizures, serotonin syndrome (hypertension, hyperthermia, myoclonus, mental status changes), opioid toxicity, and increased concentrations of tramadol and decreased concentrations of tramadol active metabolite |
| Warfarin + aspirin               | 3                  | Fair          | Increased risk of bleeding                                                      |
| Warfarin + azithromycin          | 2                  | Good          | Increased risk of bleeding                                                      |
| Warfarin + ciprofloxacin         | 3                  | Good          | Increased risk of bleeding                                                      |
including cardiovascular diseases are more common than infectious diseases. Unlike in developed countries, health insurance policy for the elderly which provides more access to medications is not introduced in this study set-up. In this study, 62.2 % of the respondents were exposed to at least one potential DDI [including contraindicated (3.6 %), major (32.9 %) and moderate (25.7 %)]. The prevalence of major and moderate DDI in the current study is in line with the findings by Luca et al. [31] and Lea et al. [32], which reported a prevalence of 63.5, 60.5 % potential DDIs respectively. In contrast to this study, lower prevalence of DDIs was reported from other studies focusing on elderly outpatients [33–35]. This indicates that drug interactions are more common in inpatients set-up as compared to outpatients probably due to the difference in number of drugs prescribed per patient.

In this study polypharmacy (taking five drugs or more) was identified as predictor for the occurrence of DDI (P = 0.00; AOR 4.047; 95 % CI 1.867–8.775). A number of other studies have also identified an increase number of medications a predictor of DDI in the elderly [6, 9, 15, 30, 34–41]. A study from Brazil reported that the potential drug interaction risk when patients are taking 2–3, 4–5 and 6–7 medications was 39, 88.8 and 100 %, respectively [36]. Nearly 50 % of elderly patients take one or more medications that are not medically necessary [37]. However, in the context of the elderly, polypharmacy does not necessarily mean inappropriate. A number of elderly patients may be prescribed combination of drugs to achieve synergic therapeutic response. As the use of many drugs in the elderly is an avoidable due to the comorbidities they have, it is important not to discard important medications because of the potential risk of drug interactions. Many of the drug interactions can be minimized by using alternative medications but those that are not require awareness of the interaction to allow

| Interacting drugs | Number of patients | Documentation | Potential risks |
|-------------------|--------------------|---------------|----------------|
| Warfarin + clarithromycin | 3 | Good | Increased risk of bleeding |
| Warfarin + metronidazole | 6 | Good | Increased risk of bleeding |

*a Documentation based on available studies or reports: excellent, the interaction has been clearly demonstrated in well-controlled studies; good, studies strongly suggest that the interaction exists except proof of well-controlled studies; fair, available evidences are poor, but the interaction is suspected on the basis of pharmacologic considerations; or, evidences are good for an interaction of pharmacologically similar drug [24]

ND not documented, Anti TB (HRZ) anti tuberculosis (isoniazid/rifampicin/pyrazinamide)

### Table 3 Statistical association of variables with drug–drug interaction

| Variable | Category | DDI | | | Adjusted odds ratio |
|----------|----------|-----|---|---|---------------------|
| | | No | Yes | P value | |
| Sex | Male | 28 | 45 | 0.531 | 0.782 (0.363–1.686) |
| | Female | 25 | 42 | | |
| | Total | 53 | 87 | | |
| Age | 60–69 | 26 | 50 | | |
| | 70–79 | 18 | 30 | 0.858 | 0.927 (0.406–2.12) |
| | >80 | 9 | 7 | 0.143 | 0.392 (0.112–1.373) |
| | Total | 53 | 87 | | |
| Comorbidities | No | 15 | 10 | 0.241 | 0.557 (0.209–1.483) |
| | Yes | 38 | 77 | | |
| | Total | 53 | 87 | | |
| Hospital stay (days) | <10 | 35 | 38 | | |
| | ≥10 | 18 | 49 | 0.168 | 0.168 (0.795–3.726) |
| | Total | 53 | 87 | | |
| Number of drugs (polypharmacy) | <5 | 35 | 24 | 0.000 | 4.047 (1.867–8.775) |
| | ≥5 | 18 | 63 | | |
| | Total | 53 | 87 | | |

DDI: drug–drug interaction

*a Statistically significant association
for proper management and appropriate dose adjustment. In reality however we must be knowledgeable not only about DDIs; indeed, a broad understanding of how to use various drugs safely in our patients is essential.

The DDI in the current study are theoretical or potential DDIs. Though the incidence of actual DDIs is lower than that of potential DDIs, some studies have found as high as 25–47 % clinically relevance potential DDIs in the elderly [33, 41]. The occurrence of clinically important interactions depends in the presence of specific risk factors such as polypharmacy, comorbidity, age, therapeutic range and dosage of the drug [42]. A research has clearly established a strong relationship between polypharmacy leading to DDI and negative clinical consequences [14, 37]. Thus, the current study is important to make awareness on the dangerous potential interactions that could have negative clinical consequences and identify risky groups.

In this study a contraindicated drug combination was observed in four (3.6 %) patients. These interactions were involving clarithromycin with either simvastatin or ciprofloxacin. In a panel of experts, these interactions were among the highly clinically significant drug–drug interactions identified as contraindicated for concurrent use [43]. The interaction between clarithromycin and simvastatin increases the risk of myopathy or rhabdomyolysis [24, 43] and myopathy was the third commonest ADR caused by DDI next to gastrointestinal bleeding and hyperkalemia [15]. Concurrent use of clarithromycin and ciprofloxacin is contraindicated due to the increased risk of QT interval prolongations [24, 43]. Probably these interactions can be avoided with the use of alternative antibiotics with similar spectrum of activity but less potential for interactions.

The most frequently prescribed major DDIs in the current study were the combination of aspirin with anticoagulants (heparin or warfarin) and/or clopidogrel; warfarin with antibiotics and spironolactone with enalapril in decreasing order of prevalence. Low-dose aspirin with clopidogrel and/or anticoagulants is increasingly prescribed in combinations to the elderly to prevent atherothrombotic events. A number of studies have identified these interactions responsible for the greatest number of serious bleedings [15, 30, 39, 44]. However, these combinations are sometimes unavoidable and might be indicated. Thus, careful monitoring and evaluation of the risk of actual drug-interaction and benefits of continuing both medications is vital. When co-administration of these drugs is required laboratory values such as international normalized ratio, signs and symptoms of bleeding should be closely monitored.

Co-administration of potassium sparing diuretic (spironolactone) with potassium supplements or angiotensin converting enzyme (ACE) inhibitors like enalapril where observed in this study. Concomitant use of these agents increases the risk of hyperkalemia and the elderly are more sensitive to this adverse effect. Other studies also reported these combinations as one of the clinically relevant DDI [15, 44–47]. A nested case control study by Juurlink et al. [47], showed that elderly patients treated with ACE inhibitor admitted with hyperkalemia were about 20 times more likely to have been treated with potassium sparing diuretic (adjusted odds ratio 20.3; 95 % confidence interval 13.4–30.7).

Many of the potential DDI in the elderly can be avoided with close patient monitoring or the use of alternative medications. However, it may be difficult for clinicians to memorize the thousands of DDIs and their clinical significance. Clinical pharmacist can play a role in identification and monitoring of potential DDIs hence to make appropriate dosage or therapy adjustments. Studies are conflicting whether clinical pharmacist interventions such as pharmaceutical care and educational campaigns in improving distal health outcomes [37, 48, 49]. However, overall improvement in quality of prescribing, use of appropriate polypharmacy hence reduced potential DDIs were observed [37, 49]. Indeed, decision support systems and information technologies are nowadays increasingly utilized to prevent severe DDIs. Despite the alert fatigue that has been identified as a major limitation in using these technologies, clinical pharmacist assisted computerized decision support systems was found to be efficient and offer an opportunity to detect potential DDIs [50].

The current study provides insight into the prevalence of potential DDIs in elderly inpatients in a resource constrained setting. In addition, it was possible to identify polypharmacy as a risk factor for the occurrence of DDI in the elderly which have been observed in other studies. However, the study has some limitations: one the study was done on small number of elderly patients compared to other studies. Second, being a cross sectional study which was carried out at one time point, it was not possible to see the outcome of the potential DDI or the actual occurrence of the interactions from a clinical viewpoint. Further longitudinal studies using larger number of participants are necessary.

**Conclusion**

The finding of present study reveals that nearly two-third of the elderly patients are exposed to at least one potential DDIs. Elderly patients on five or more medications need close monitoring as they are four times at higher risk of having DDIs (Additional file 1). Identifying and preventing potentially harmful DDIs is a critical component of a pharmacist’s mission and the clinical pharmacist must remain vigilant in monitoring
potential DDIs and making appropriate dosage or therapy adjustments.

Additional files

- Additional file 1. Dataset.
- Additional file 2. STROBE Statement—checklist of items that should be included in reports of observational studies.

Abbreviations
ADRs: adverse drug reactions; AOR: adjusted odds ratio; ACE: angiotensin converting enzyme; ARH: Ayder Referral Hospital; CI: confidence interval; CV: cardiovascular; DDIs: drug–drug interactions; ND: not documented; SD: standard deviation; SPSS: statistical package for social sciences; UN: United Nations.

Authors’ contributions
FT, GT and EA contributed to the study design, data collection and data processing. GT and TT developed the draft manuscript which was finalized with the input of all authors. All authors have contributed to the interpretation of findings and revision of the manuscript. All authors have read and approved the final manuscript.

Author details
1 Forecasting and Capacity Building Directorate, The Federal Democratic Republic of Ethiopia Pharmaceutical Fund and Supply Agency, Addis Ababa, Ethiopia. 2 Clinical Pharmacy Course and Research Unit, Department of Pharmacy, College of Health Sciences, Mekelle University, Mekelle, Ethiopia. 3 Pharmacoepidemiology and Social Pharmacy Course and Research Unit, Department of Pharmacy, College of Health Sciences, Mekelle University, Mekelle, Ethiopia.

Acknowledgements
The authors would like to thank the study participants and the hospital management for their cooperation during the study. We would like to thank Mr. Negash Shiferaw for his inevitable role during the data collection.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The dataset supporting the conclusions of this study is included within the article and in the additional files.

Adherence to STROBE guidelines
A report of STROBE Statement to show adherence to STROBE guideline for cross sectional study is added in this article as Additional file 2.

Ethics approval and consent to participate
This study was approved by the Health research Ethics Review Committee of the College of Health Sciences, Mekelle University, Ethiopia. Participants’ medication profile was reviewed after obtaining verbal consent from each participant. Prior to obtaining consent, information about the study aims, benefits and risks to participants was provided. Participants were also assured about the confidentiality of the data.

Received: 7 October 2015 Accepted: 25 August 2016 Published online: 01 September 2016

References
1. WHO. Definition of an older or elderly person. 2016. http://www.who.int/healthinfo/survey/ageingdefinholder/en/. Accessed 18 April 2016.
2. Ministry of Labour and Social Affairs. General Situation of the Elderly. 2016. http://www.moka.gov.et/English/SWD/Pages/SituationofElderly.aspx. Accessed 18 April 2016.
3. ICH final guideline on special populations: Geriatrics (E7). Released June 1993.
4. Davies EA, O'Mahony MS. Adverse drug reactions in special populations—the elderly. Br J Clin Pharmacol. 2015;80:796–807.
5. Mangoni A, Jackson S. Age related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57:6–14.
6. Marzolini C, Back D, Weber R, Furrer H, Cavassini M, Calmy A, Vernazza P, Bernasconi E, Khoo S, Battegay M, et al. Ageing with HIV: medication use and risk for potential drug–drug interactions. J Antimicrob Chemother. 2011;66(8):2107–11.
7. Mallet L, Spinnwinie A, Huang A. The challenge of managing drug interactions in elderly people. Lancet. 2007;370:85–91.
8. Guay D. The pharmacology of aging. In: Fillit H, Rockwood K, Woodhouse K, editors. Brocklehurst’s textbook of geriatrics and clinical gerontology. 7th ed. London: Saunders; 2010. p. 138–44.
9. Hadjibabaei M, Badri S, Ateii S, Mosleh AH, Karimzadeh I, Ghavamzadeh A. Potential drug–drug interactions at a referral hematology—oncology ward in Iran: a cross-sectional study. Cancer Chemother Pharmacol. 2013;71(6):1619–27.
10. Riechelmann RP, Del Giglio A. Drug interactions in oncology: how common are they? Ann Oncol. 2009;20(12):1907–12.
11. Uijtendaal EV, van Harsse1 LL, Hugenhi1tz G, Kuck EM, Zwart-van Rijkom JE, Cramer OL, Egberts TC. Analysis of potential drug–drug interactions in medical intensive care unit patients. Pharmacotherapy. 2014;34(3):213–9.
12. Bernstein L, Lopez-Valcarcel BG, Petersen G. Risk factors for potential drug interactions in general practice. Eur J Gen Pract. 2008;14:23–9.
13. Delafuente CJ. Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol. 2003;48:133–43.
14. Saeddier EA, Lubé M, Nielsen LP, Bønnenerup DK, Brock B. Number of drugs most frequently found to be independent risk factors for serious adverse reactions: a systematic literature review. Br J Clin Pharmacol. 2015;80:808–17.
15. Obreli-Neto PR, Nobilli A, de Oliveira Baldoni A, Guidoni CM, de Lyra Júnior DP, Pilger D, Duzanski J, Tettamanti M, Cruciol-Souza JM, Gaeti WP, Nakamura Cuman RK. Adverse drug reactions caused by drug–drug interactions in elderly outpatients: a prospective cohort study. Eur J Clin Pharmacol. 2012;68(12):1667–76.
16. Bucja C, Farcaş A, Cazacu I, Leucuta D, Achimas-Cadariu A, Mogosan C, Bojita M. How many potential drug–drug interactions cause adverse drug reactions in hospitalized patients? Eur J Int Med. 2013;24(1):17–33.
17. Dechanont S, Maphanta S, Butthum B, Kongkaew C. Hospital admissions/visits associated with drug–drug interactions: a systematic review and meta-analysis. Pharmacoeconom Drug Saf. 2014;23:489–97.
18. Patel H, Bell D, Molokhia M, Srishanmuganathan J, Patel M, Car J, Majeed A. Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998–2005. BMC Clin Pharmacol. 2007;7:9.
19. Princhenened M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Drug adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329:15–9.
20. Saurat JH, Guerin A, Yu AP, Latremouille-Viau D, Wu EQ, Gupta SR, Bao Y, Mulani PM. High prevalence of potential drug–drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice. Dermatology. 2010;220(2):128–37.
21. Shad MU, Marsh C, Preskorn SH. The economic consequences of a drug–drug interaction. J Clin Psychopharmacol. 2001;21:119–20.
22. Moura C, Accurio F, Belo N. Drug–drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharmacol. 2009;61(12):166–72.
23. Mekelle University. College of Health Sciences. Ayder Referral Hospital. http://www.mu.edu.et/chs/index.php/ayder-referral-hospital. Accessed 24 Jan 2014.
24. Micromedex® HealthCare Series (internet database) Version 2.0. Greenwood Village, Colorado: Thomson Healthcare Inc. 2013. http://www.micromedexsolutions.com. Accessed 24 Jan 2014.
25. Tohi H, Faber A, van den Berg PB, Drane JW, de Jong-van den Berg LT. Studying co-medication patterns: the impact of definitions. Pharmacoepidemiol Drug Saf. 2007;16(4):405–11.
26. Valderrama JM, Starfield B, Sibbald B, Salisbury C, Roland M. Defining comorbidity: implications for understanding health and health services. Ann Fam Med. 2009;7(4):357–63.
27. WHO. Rational use of medicines. www.who.int/medicines/areas/rational_use/en/. Accessed 7 Jan 2016.
28. Lin CF, Wang CY, Bai CH. Polypharmacy, aging and potential drug–drug interactions in outpatients in Taiwan: a retrospective computerized screening study. Drugs Aging. 2011;28(3):219–25.
29. Salve KJ, Kalyansundaram D, Bapurupu Y. A study on polypharmacy and potential drug–drug interactions among elderly patients admitted in Department of Medicine of a Tertiary Care Hospital in Puducherry. J Clin Diagn Res. 2016;10(2):FC06–10.
30. Kashyap M, D’Cruz S, Sachdev A, Tiwari P. Drug–drug interactions and their predictors: results from Indian elderly inpatients. Pharm Pract. 2013;11(4):191–5.
31. Pasina L, Djade CD, Nobili A, Tettamanti M, Franchi C, Salerno F, Corroa S, Marengoni A, Iorio A, Marucci M, Mannucci PM. Drug–drug interactions in a cohort of hospitalized elderly patients. Pharmacoepidemiol Drug Saf. 2013;22:1054–60.
32. Lea M, Roqnan SE, Koristovic R, Wyller TB, Molden E. Severity and management of drug–drug interactions in acute geriatric patients. Drugs Aging. 2013;30(9):721–7.
33. Tulner LR, Frankfort SV, Gijsen GJ, van Campen JP, Beijnen JH. Drug–drug interactions in a geriatric outpatient cohort: prevalence and relevance. Drugs Aging. 2008;25(4):343–55.
34. Mibielli P, Rozenfeld S, Matos GC, Fde Acurcio A. Potential drug–drug interactions among elderly using antihypertensives from the Brazilian list of essential medicines. Cad Saude Pub. 2014;30(9):1947–56.
35. Secoli SR, Figueras A, Lebrão ML, de Lima FD, Santos JL. Risk of potential drug–drug interactions among Brazilian elderly: a population-based, cross-sectional study. Drugs Aging. 2010;27(9):759–70.
36. Mendes-Nett RS, Silva CQ, Oliveira-Filbo AD, Rocha CE, Lyra-Junior DP. Assessment of drug interactions in elderly patients of a family healthcare unit in Aracaju (Brazil): a pilot study. AFR J Pharm Pharmacol. 2011;5:812–8.
37. Maher RH, Hanlon JT, Hajar BR. Clinical Consequences of Polypharmacy in Elderly. Expert Opin Drug Saf. 2014;13(1):57–65. doi:10.1517/14740338.2013.827660.
38. Nobili A, Pasina L, Tettamanti M, Lucca U, Riva E, Marzona I, Monesi L, Cucchiari R, Bortolotti A, Fortino I, Merlino L, Walter Locatelli G, Giuliani G. Potentially severe drug interactions in elderly outpatients: results of an observational study of an administrative prescription database. J Clin Pharm Ther. 2009;34(4):377–86.
39. Bogetti-Salazar M, González-González C, Juárez-Cedillo T, Sánchez-García S, Rosas-Carrasco O. Severe potential drug–drug interactions in older people with dementia and associated factors. Clinics. 2016;71(1):17–21.
40. Obreli Neto PR, Nobili A, de Lyra DP Jr, Pilger D, Guidoni CM, de Oliveira Baldoni A, Crucio-Souza JM, de Carvalho Freitas AL, Tettamanti M, Gaeti WP, Nakamura Cuman RK. Incidence and predictors of adverse drug reactions caused by drug–drug interactions in elderly outpatients: a prospective cohort study. J Pharm Pharm Sci. 2012;15(2):332–43.
41. Obreli Neto PR, Nobili A, Marusic S, Pilger D, Guidoni CM, Baldoni Ade O, Crucio-Souza JM, Da Cruz AN, Gaeti WP, Cuman RK. Prevalence and predictors of potential drug–drug interactions in the elderly: a cross-sectional study in the Brazilian primary public health system. J Pharm Pharm Sci. 2012;15(2):344–54.
42. Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug–drug interactions. Expert Opin Drug Saf. 2012;11(1):83–94.
43. Phansalkar S, Desai AA, Bell D, Yoshida E, Doole J, Czochanski M, Midleton B, Bates DW. High-priority drug–drug interactions for use in electronic health records. J Am Med Inform Assoc. 2012;19(5):735–43.
44. Hines LE, Murphy JE. Potentially harmful drug–drug interactions in the elderly: a review. Am J Geriatr Pharmacother. 2011;9(6):364–77.
45. Oertle M. Frequency and nature of drug–drug interactions in a Swiss primary and secondary acute care hospital. Swiss Med Wkly. 2012;142:w13522.
46. Eschmann E, Beeler PE, Kaplan V, Schneemann M, Zünd G, Blaser J. Clinical decision support for monitoring drug–drug interactions and potassium-increasing drug combinations: need for specific alerts. Stud Health Technol Inform. 2012;180:1200–2.
47. Jurjulik DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug–drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003;289(13):1652–8.
48. Patterson SM, Cadogan CA, Kense N, Cardwell CR, Bradley MC, Ryan C, Hughes C. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2014;10:CD008165.
49. Raschi E, Piccinni C, Signoretta V, Lionello L, Bonezzi S, Delfino M, Di Candia L, Di Castrì L, Pieraccini F, Carati D, Poluzzi E, DE Ponti F, Emilia-Romagna elderly poly-treated patients research group. Clinically important drug–drug interactions in poly-treated elderly outpatients: a campaign to improve appropriateness in general practice. Br J Clin Pharmacol. 2015;80(6):1411–20.
50. Helmoms PJ, Suijkerveij B, Nannan Panday PV, Kosterink JG. Drug–drug interaction checking assisted by clinical decision support: a return on investment analysis. J Am Med Inform Assoc. 2015;22(4):764–72.